Steve Schonfeld’s Pliant Therapeutics PLRX Stock Holding History

Steve Schonfeld’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-8,582	Closed	-$228K	–	2418
2023 Q1	$228K	Buy	+8,582	New	+$244K	﹤0.01%	1489
2022 Q4	–	Sell	-10,000	Closed	-$209K	–	2914
2022 Q3	$209K	Sell	10,000 -9,100	-48%	-$174K	﹤0.01%	2308
2022 Q2	$153K	Buy	+19,100	New	+$122K	﹤0.01%	1994

Other funds holding PLRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Steve Schonfeld's PLRX Position: Q2 2023 in Review

Steve Schonfeld sold out of Pliant Therapeutics (PLRX) in Q2 2023, closing a stake of 8,582 shares — an estimated $228K sold.

Steve Schonfeld first reported a position in PLRX in Q2 2022 and held it in 3 quarters. The position peaked at $228K in Q1 2023. 144 funds tracked by Wall St. Rank hold PLRX as of Q2 2023.

Steve Schonfeld reported no remaining Pliant Therapeutics position as of Q2 2023 after selling out during the quarter.
Steve Schonfeld sold 8,582 Pliant Therapeutics shares in Q2 2023, an estimated $228K.
Steve Schonfeld first reported a position in Pliant Therapeutics in Q2 2022 and held it in 3 quarters.
Steve Schonfeld's Pliant Therapeutics position peaked at $228K in Q1 2023.
144 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2023.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.